Paul Moorehead/LinkedIn
Aug 6, 2025, 10:47
Conquering Factor VIII Inhibitors: New Insights Into the ‘Devil’ of Hemophilia A Treatment Resistance
Flora Peyvandi posted on X:
”Exorcizing the devil of factor VIII inhibitors”
“For the Devil is a gentleman, and doesn’t keep his word” – G.K. Chesterton
In this issue of Blood Advances, Butera et al shed some light on the mystery of factor VIII (FVIII) inhibitors, the most diabolical complication of FVIII replacement therapy in patients with hemophilia A. Their work examined the impact of disulfide bonds on the antigenicity of the FVIII molecule, with possible implications for the understanding of immune responses to exogenous FVIII and for drug design.
Read the full article here.
Auothor: Paul C. Moorehead
Stay updated with Hemostasis Today.
-
Nov 14, 2025, 11:58Marilena Vrana: Can Public-only Blood Collection Systems Meet the Growing Patient Need for PDMs?
-
Nov 14, 2025, 11:48Cedric Hermans Shares the 1st Illustrated Review Dedicated to Hemophilia B
-
Nov 14, 2025, 10:28Valance Washington: Proud to Share Our Lab’s Latest Publication in Platelets Journal
-
Nov 14, 2025, 10:18Sripal Bangalore and Ajay Kirtane on TUXEDO-2 Comparison Focusing on Diabetic Patients
-
Nov 14, 2025, 10:11Ashley Lawrenson on Her Coagulation Journey Using Automation With the HemoCell and HemoHub
-
Nov 14, 2025, 10:05Kingsley Wheaton: A Year Ago, Omni Was an Idea – Today, It’s a Movement!
-
Nov 14, 2025, 09:58Rucha Patil Takes The National DHR-ICMR Gold Award for Best Technology
-
Nov 14, 2025, 09:48Caitlin Raymond on ”The Plasma Chasers”
-
Nov 14, 2025, 09:42Erin VanDyke on Why They Do In-person Site Visits for NBCA Centers of Excellence Designation!